Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 3Phase 3 1

Status

Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Gynecologic 2Breast 1

Conditions

Ovarian Neoplasms 8Breast Neoplasms 8Prostatic Neoplasms 5Small Cell Lung Carcinoma 4Stomach Neoplasms 3Neoplasms 3Lung Neoplasms 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Recurrence 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Glioma 2Uterine Neoplasms 1Urogenital Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Pheochromocytoma 1Peritoneal Neoplasms 1Paraganglioma 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms by Site 1Metastatic Castration-Resistant Prostate Cancer 1Meningioma 1

Interventions

pembrolizumab 26Paclitaxel 22Oxaliplatin 20Nivolumab 16Docetaxel 16Capecitabine 16Cisplatin 15Fluorouracil 11Cyclophosphamide 11fludarabine 10S 1 (combination) 10Trastuzumab 9Irinotecan 9Carboplatin 8Leucovorin 7tislelizumab 6aldesleukin 5Ramucirumab 5Interleukin-2 5Gemcitabine 5Drug Therapy 5Bevacizumab 5sintilimab 4fludarabine phosphate 4apatinib 4Radiotherapy 4Everolimus 4regorafenib 3olaparib 3durvalumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Stomach Neoplasms × olaparib × Clear all
NCT02734004 2026-04-20

MEDIOLA

AstraZeneca

Phase 1/2 Active not recruiting
264 enrolled 32 charts
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT07453394 2026-03-06

QLS5132 Combination Therapy in Advanced Solid Tumors

Qilu Pharmaceutical Co., Ltd.

Phase 1/2 Not yet recruiting
626 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT03008278 2026-02-03

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Completed
51 enrolled 20 charts
Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡